Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - meningococcal polysaccharide group a,meningococcal polysaccharide group c,meningococcal polysaccharide group w135,meningococcal polysaccharide group y,tetanus toxoid -

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (not less than); hepatitis b surface antigen, recombinant 10ug; pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (/dose); polio virus type 2 8 dagu (/dose); polio virus type 3 32 dagu (/dose); tetanus toxoid, adsorbed 40 [iu] (not less than); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 30 [iu] (not less than) hepatitis b surface antigen, recombinant 10ug pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (/dose) polio virus type 2 8 dagu (/dose) polio virus type 3 32 dagu (/dose) tetanus toxoid, adsorbed 40 [iu] (not less than) excipient: aluminium medium 199 sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms) excipient: aluminium as aluminium phosphate lactose - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b.

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid, diphtheria toxoid, haemophilus type, b polysaccharide, polyribosylribitol phosphate, conjugated to, as carrier, protein, bordetella pertussis - powder and suspension for suspension for injection - diphtheria toxoid haemophilus type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid as carrier protein 10 µg bordetella pertussis 4 iu tetanus toxoid 60 iu - vaccines

Canada - English - Health Canada

glaxosmithkline inc - meningococcal group a oligosaccharide; meningococcal group c oligosaccharide; meningococcal group w-135 oligosaccharide; meningococcal group y oligosaccharide; corynebacterium diphtheriae crm-197 protein - solution - 10mcg; 5mcg; 5mcg; 5mcg; 47mcg - meningococcal group a oligosaccharide 10mcg; meningococcal group c oligosaccharide 5mcg; meningococcal group w-135 oligosaccharide 5mcg; meningococcal group y oligosaccharide 5mcg; corynebacterium diphtheriae crm-197 protein 47mcg - vaccines

Canada - English - Health Canada

glaxosmithkline inc - recombinant neisseria meningitidis group b nhba fusion protein; recombinant neisseria meningitidis group b nada protein; recombinant neisseria meningitidis group b fhbp fusion protein; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) - suspension - 50mcg; 50mcg; 50mcg; 25mcg - recombinant neisseria meningitidis group b nhba fusion protein 50mcg; recombinant neisseria meningitidis group b nada protein 50mcg; recombinant neisseria meningitidis group b fhbp fusion protein 50mcg; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) 25mcg - vaccines

United States - English - NLM (National Library of Medicine)

homeocare laboratories - haemophilus influenzae type b (unii: f2tw0n64fi) (haemophilus influenzae type b - unii:f2tw0n64fi) - haemophilus influenzae type b 9 [hp_c] in 29.5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - haemophilus parasuis (serovar 4) strain 2170b - unknown - haemophilus parasuis (serovar 4) strain 2170b vaccine-microbial active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - haemophilus parasuis (serovar 5) strain 1a84-29755 - unknown - haemophilus parasuis (serovar 5) strain 1a84-29755 vaccine-microbial active 0.0 - active constituent

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis filamentous, haemagglutinin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg pertussis filamentous haemagglutinin 25 µg pertussis toxoid 25 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml diphtheria toxoid haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines